Advanced Life Sciences Holdings, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
- The report contains detailed information about Advanced Life Sciences Holdings, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Advanced Life Sciences Holdings, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Advanced Life Sciences Holdings, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Advanced Life Sciences Holdings, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Advanced Life Sciences Holdings, Inc. business.
About Advanced Life Sciences Holdings, Inc.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs in the areas of infectious disease, oncology, and respiratory disease.
Primary Programs
Infectious Disease-Respiratory Tract Infections: The company has a worldwide license (excluding Japan) from Abbott Laboratories (Abbott) to develop and commercialize cethromycin (Restanza), a second generation, once-a-day antibiotic for the treatment of respiratory tract infections.
Infectious Disease-Biodefense: Along with its clinical work in the treatment of community acquired pneumonia (CAP), the company collaborates with several groups within the U.S. Government to evaluate cethromycin's potential in preventing inhalation anthrax and other high-priority bioterror agents.
Oncology: ALS-357 is a compound that has shown evidence of anti-tumor activity against malignant melanoma in preclinical studies. The company established an open investigational new drug application (IND) for ALS-357 with the FDA (the Food and Drug Administration) and has begun screening patients in a Phase I/II escalating dose study for the topical treatment of cutaneous melanoma.
Respiratory Disease: ALS-886 is a novel therapeutic in preclinical development for the treatment of inflammation-related tissue damage, including tissue damage associated with acute respiratory distress syndrome (ARDS). The company established an IND application for ALS-886 with the FDA.
Collaborations
In 2004, the company entered into an agreement with Abbott Laboratories under which it acquired from Abbott a license to certain patent applications, patents and proprietary technology relating to cethromycin.
In 2008, the company entered into a development and commercialization agreement with Pfizer for cethromycin in the Asia Pacific region excluding Japan. The company retains exclusive rights to cethromycin in the rest of the world, including North America and Europe excluding Japan.
University of Illinois at Chicago (UIC): The company acquired a worldwide license, to develop, make, use, and sell ALS-357 and related compounds to treat melanoma and other forms of cancer. The company also has collaboration with Baxter International and obtains the right, title, and interest to patented inventions relating to ALS-886.
On July 27, 2010, Advanced Life Sciences Holdings, Inc. announced it has entered into a sponsored research and option agreement with The University of British Columbia to develop antimicrobial peptides.
In November 2010, Advanced Life Sciences Holdings, Inc. announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with Walter Reed Army Institute of Research. The purpose of this CRADA is to allow The Walter Reed Army Institute of Research to perform advanced animal efficacy testing of Restanza (cethromycin), the company's novel oral antibiotic, against various Plasmodium species that cause malaria.
Competition
The companys competitors include Aventis, Pfizer, GlaxoSmithKline, and Johnson & Johnson.
History
Advanced Life Sciences Holdings, Inc. was founded in 1999.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
RESEARCH METHODOLOGY
DISCLAIMER
1. ADVANCED LIFE SCIENCES HOLDINGS, INC. COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. ADVANCED LIFE SCIENCES HOLDINGS, INC. BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. ADVANCED LIFE SCIENCES HOLDINGS, INC. SWOT ANALYSIS
3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats
4. ADVANCED LIFE SCIENCES HOLDINGS, INC. FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. ADVANCED LIFE SCIENCES HOLDINGS, INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Advanced Life Sciences Holdings, Inc. Direct Competitors
5.2. Comparison of Advanced Life Sciences Holdings, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Advanced Life Sciences Holdings, Inc. and Direct Competitors Stock Charts
5.4. Advanced Life Sciences Holdings, Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Advanced Life Sciences Holdings, Inc. Industry Position Analysis
6. ADVANCED LIFE SCIENCES HOLDINGS, INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. ADVANCED LIFE SCIENCES HOLDINGS, INC. EXPERTS REVIEW1
7.1. Experts Consensus
7.2. Experts Revisions
8. ADVANCED LIFE SCIENCES HOLDINGS, INC. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. ADVANCED LIFE SCIENCES HOLDINGS, INC. IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. ADVANCED LIFE SCIENCES HOLDINGS, INC. PORTER FIVE FORCES ANALYSIS2
12. ADVANCED LIFE SCIENCES HOLDINGS, INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF FIGURES
Advanced Life Sciences Holdings, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Advanced Life Sciences Holdings, Inc. 1-year Stock Charts
Advanced Life Sciences Holdings, Inc. 5-year Stock Charts
Advanced Life Sciences Holdings, Inc. vs. Main Indexes 1-year Stock Chart
Advanced Life Sciences Holdings, Inc. vs. Direct Competitors 1-year Stock Charts
Advanced Life Sciences Holdings, Inc. Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Advanced Life Sciences Holdings, Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Advanced Life Sciences Holdings, Inc. Key Executives
Advanced Life Sciences Holdings, Inc. Major Shareholders
Advanced Life Sciences Holdings, Inc. History
Advanced Life Sciences Holdings, Inc. Products
Revenues by Segment
Revenues by Region
Advanced Life Sciences Holdings, Inc. Offices and Representations
Advanced Life Sciences Holdings, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Advanced Life Sciences Holdings, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Advanced Life Sciences Holdings, Inc. Capital Market Snapshot
Advanced Life Sciences Holdings, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Advanced Life Sciences Holdings, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Advanced Life Sciences Holdings, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1
SWOT Analysis
SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL Analysis
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO Analysis
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Financial
- Physical
- Technological
- Organizational
- Intangible resources
- Human
- Innovation and Creativity
- Reputation
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Valuable?
- Rare?
- Costly to imitate?
- Organized properly?
